Magnetocardiographic demonstration of complex ventricular preexcitation resulting in ablation failure

Brisinda, Donatella; Venuti, A; Sorbo, Anna Rita; Fenici, Riccardo

doi:10.1016/j.ijcard.2013.07.215

Cited by 6 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, although experience is still limited to only few institution, contactless MCG is one of the most promising technology for non‐invasive cardiac electro‐anatomical imaging and accurate localization of arrhythmogenic substrates (Brisinda, Venuti, Sorbo, & Fenici, ; Fenici & Brisinda, ; Fenici, Brisinda, Venuti, & Sorbo, ; Kwong, Leithäuser, Park, & Yu, ). Several studies, all carried out in magnetically shielded rooms, have demonstrated the usefulness of MCG to study AF (Jurkko et al, , ; Kim & Ahn, ; Kim, Kim, Lee, & Ahn, ; Koskinen et al, ; Lehto et al, ; Lim et al, ; Mäntynen et al, ; Nakai et al, ; Sato et al, ; Yamada & Yamaguchi, ; Yamada, Tsukada, Miyashita, Kuga, & Yamaguchi, ; Yoshida et al, ).…”

Section: Discussionmentioning

confidence: 99%

Predictive value of unshielded magnetocardiographic mapping to differentiate atrial fibrillation patients from healthy subjects

Guida

Sorbo

Fenici

et al. 2018

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of unshielded magnetocardiographic mapping to differentiate atrial fibrillation patients from healthy subjects

Guida

Sorbo

Fenici

et al. 2018

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

“…Interesting data were also obtained in patients with non-ischemic arrhythmogenic cardiomyopathy ( 96 , 138 , 218 , 219 ), confirmed also by more recent multichannel MCG studies in MSRs ( 220 , 221 ). Further experimental ( 222 ) and clinical research has confirmed the reliability of unshielded MCG mapping as a unique method for the contactless ambulatory study of myocardial ischemia, for fetal MCG ( 223 , 224 ), for risk assessment, and for follow-up of asymptomatic Brugada patients ( 225 ) to identify patients with complex ventricular preexcitation ( 226 ).…”

Section: Unshielded Mcg: the Pastmentioning

confidence: 94%

“…While clinical studies, which was carried out in specialized centers with shielded and unshielded SQUID-based MCG systems, enhanced the evidence for MCG 3D electroanatomical localization accuracy and for risk assessment of arrhythmogenic mechanisms/substrates ( 82 , 83 , 90 , 226 , 245 – 251 ), a renewed interest for biomagnetic sensor technology has raised again not only at the academic but also at the industrial level ( 252 , 253 ). In fact, apart from the traditionally available multichannel cryogenic MCG systems working in MSRs ( 246 , 254 – 259 ) and a more downscaled price for sequential unshielded MCG mapping ( 77 , 256 – 259 ), three younger companies have manufactured innovative multichannel MCG devices, based on different sensor technologies, all of them specifically designed for clinical application at minimized running costs and with optimized operational simplicity.…”

Section: Unshielded Mcg: the Presentmentioning

confidence: 99%

Clinical magnetocardiography: the unshielded bet—past, present, and future

Brisinda,

Fenici,

Fenici

2023

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Magnetocardiography (MCG), which is nowadays 60 years old, has not yet been fully accepted as a clinical tool. Nevertheless, a large body of research and several clinical trials have demonstrated its reliability in providing additional diagnostic electrophysiological information if compared with conventional non-invasive electrocardiographic methods. Since the beginning, one major objective difficulty has been the need to clean the weak cardiac magnetic signals from the much higher environmental noise, especially that of urban and hospital environments. The obvious solution to record the magnetocardiogram in highly performant magnetically shielded rooms has provided the ideal setup for decades of research demonstrating the diagnostic potential of this technology. However, only a few clinical institutions have had the resources to install and run routinely such highly expensive and technically demanding systems. Therefore, increasing attempts have been made to develop cheaper alternatives to improve the magnetic signal-to-noise ratio allowing MCG in unshielded hospital environments. In this article, the most relevant milestones in the MCG's journey are reviewed, addressing the possible reasons beyond the currently long-lasting difficulty to reach a clinical breakthrough and leveraging the authors’ personal experience since the early 1980s attempting to finally bring MCG to the patient's bedside for many years thus far. Their nearly four decades of foundational experimental and clinical research between shielded and unshielded solutions are summarized and referenced, following the original vision that MCG had to be intended as an unrivaled method for contactless assessment of the cardiac electrophysiology and as an advanced method for non-invasive electroanatomical imaging, through multimodal integration with other non-fluoroscopic imaging techniques. Whereas all the above accounts for the past, with the available innovative sensors and more affordable active shielding technologies, the present demonstrates that several novel systems have been developed and tested in multicenter clinical trials adopting both shielded and unshielded MCG built-in hospital environments. The future of MCG will mostly be dependent on the results from the ongoing progress in novel sensor technology, which is relatively soon foreseen to provide multiple alternatives for the construction of more compact, affordable, portable, and even wearable devices for unshielded MCG inside hospital environments and perhaps also for ambulatory patients.

show abstract